No Data
NIH Outlays Rise by 5% in June, Says Baird
These Are the Stocks With the Highest Increase in Short Interest Within Life Sciences and Diagnostics - Baird
Morgan Stanley Maintains Qiagen NV(QGEN.US) With Buy Rating, Cuts Target Price to $47.62
Morgan Stanley analyst Aisyah Noor maintains $Qiagen NV(QGEN.US)$ with a buy rating, and adjusts the target price from $51 to $47.62.According to TipRanks data, the analyst has a success rate of 33.3%
QIAGEN Announces Partnership With The Snow Molecular Anthropology Lab At The University Of Montana In The Fields Of Human Identification And Forensics To Enhance The Identification Of Human Remains
QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA))))) today announced a partnership with the Snow Molecular Anthropology Lab at the University of Montana in the fields of human identification and fore
Express News | Qiagen NV : Morgan Stanley Cuts Target Price to $47 From $51
QIAGEN N.V. to Release Results for Q2 2024 and Hold Webcast
Venlo, The Netherlands, July 02, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the second quarter 2024. Press release date / time: Wednesday,